Speaker illustration

Professor Pier Lambiase

University College London, London (United Kingdom of Great Britain & Northern Ireland)

Member of:

European Heart Rythm Association

Prof. Pier Lambiase is Professor of Cardiology at UCL & leads the Inherited arrhythmia service at Barts Heart Centre aswell as the clinical electrophysiology research group. He has published widely on arrhythmia mechanisms in specific inherited conditions and co-authored/advised national & international guidelines on genetic diagnosis aswell as sudden death prevention in inherited ion channel disorders (JACC 2015-2016, ESC 2021). He described the arrhythmogenic phenotypes in Brugada Syndrome (Circulation 2009) and ARVC (Eur Ht J, 2012). He has published over 200 peer review papers and raised >£5M in grants from BHF, Welcome Trust & MRC over the past 5 years & was awarded the BCS Michael Davies early career research award in 2015. He leads a biomedical engineering group to utilise high density electrical mapping data to enable deep phenotyping of specific gene mutation carriers aswell as UK Biobank population data combining genomic and physiological parameters (MRC project grant).

Inherited diseases and ventricular arrhythmias

Event: ESC Congress 2021 - The Digital Experience

Topic: Ventricular Arrhythmias and Sudden Cardiac Death (SCD)

Session type: Abstract Sessions

Thumbnail

Meet the Experts - Brugada Syndrome: all you need to know

Event: ESC CONGRESS 2019

Topic: Ion Channel Disorders

Session type: Focus with the Experts

Thumbnail

Devices in inherited cardiac conditions

Event: EHRA 2018

Topic: Device Therapy

Session type: How To ...

Thumbnail

Inherited arrhythmogenic diseases: genetics, risk stratification and sudden cardiac death

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Molecular biology / genetics

Session type: New ESC Guidelines

Thumbnail

Prediction of sudden death: do we have a crystal ball?

Event: ESC CONGRESS 2016

Topic: Sudden death / resuscitation

Session type: Advances in Science

Thumbnail

This platform is supported by

logo Novo Nordisk